NEW YORK – HalioDx and OSE Immunotherapeutics on Wednesday announced they will conduct a translational investigation to identify potential immune biomarkers for a non-small cell lung cancer treatment.
Marseille, France-based HalioDx will perform immune biomarker exploratory work as part of the collaboration. The work will focus on the testing and analysis of clinical biopsy tissue samples from participating patients in the ongoing Phase III Atalante 1 clinical trial of Nante, France-based OSE Immunotherapeutics' neoepitope combination Tedopi. The goal is to define "the profile of responder patients to Tedopi treatment in advanced lung cancer," OSE Immunotherapeutics CEO Alexis Peyroles said in a statement.
Financial and other terms of the deal were not disclosed.
Tedopi is being evaluated in the Atalante 1 trial in advanced NSCLC for HLA-A2-positive patients for whom treatment with PD-L1 checkpoint inhibitors was unsuccessful. Results from the first step of the Phase III trial are expected by the end of the first quarter of 2020. Tedopi is also being studied in an ongoing Phase II trial in pancreatic cancer patients, the partners said.